A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3230-3237

  Boucher, Paul D ^a   Im, Michael M ^a   Freytag, Svend O ^b   Shewach, Donna S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; DEOXYGUANOSINE; DEOXYGUANOSINE TRIPHOSPHATE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; PRODRUG; RIBONUCLEOTIDE REDUCTASE; THYMIDINE TRIPHOSPHATE;

ALLOSTERISM; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL DEATH; CELL KILLING; CYTOTOXICITY; DRUG MECHANISM; FUSION GENE; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; SUICIDE GENE THERAPY; TUMOR GROWTH;

ADENOVIRIDAE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYTOSINE DEAMINASE; DEOXYGUANOSINE; DEOXYRIBONUCLEOTIDES; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 33645509483     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3033     Document Type: Article

References (44)

1. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy for cancer: historical appraisal and future prospectives. J Cell Physiol 2001;187:22-36.
2. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A 1992;89:33-7.
3. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1:279-87.
4. Myers CE. The pharmacology of the fluoropyrimidines. Pharmacol Rev 1981;33:1-15.
5. Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogues. J Biol Chem 1989;264:19039-44.
6. Tomicic MT, Thust R, Kaina B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene 2002;21:2141-53.
7. Rubsam LZ, Davidson BL, Shewach DS. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-B-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. Cancer Res 1998;58:3873-82.
8. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993;4:725-31.
9. Ishii-Morita H, Agbaria R, Mullen CA, et al. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 1997;4:244-51.
10. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000;60:3989-99.
11. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
12. Dyer MR, Herrling PL. Progress and potential for gene-based medicines. Mol Ther 2000;1:213-24.
13. Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Hum Gene Ther 1999;10:2325-35.
14. Immonen A, Vapalahti M, Tyynela K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomized, control study. Mol Ther 2004;10:967-72.
15. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968-76.
16. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E.coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorcytosine. Hum Gene Ther 1997;8:985-1001.
17. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998;9:1323-33.
18. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003;63:7497-506.
19. Boucher PD, Ruch RJ, Shewach DS. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum Gene Ther 1998;9:801-14.
20. Boucher PD, Ostruska LJ, Shewach DS. Synergistic enhancement of Herpes Simplex Virus thymidine kinase/ganciclovir-mediated cytotoxicity by hydroxyurea. Cancer Res 2000;60:1631-6.
21. Rubsam LZ, Boucher PD, Murphy PJ, KuKuruga M, Shewach DS. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res 1999;59:669-75.
22. Boucher PD, Shewach DS. In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine. Mol Ther 2005;12:1064-71.
23. Aghi M, Kramm CM, Chou T, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998;90:370-80.
24. Uckert W, Kammertons T, Haack K, et al. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 1998;9:855-65.
25. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997;8:73-85.
26. Moore EC, Hurlbert RB. Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors. J Biol Chem 1966;241:4802-9.
27. Xie Y, Gilbert JD, Kim JH, Freytag SO. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin Cancer Res 1999;5:4224-32.
28. Shewach DS. Quantitation of deoxyribonucleoside 5′-triphosphates by a sequential boronate and anion-exchange high-pressure liquid chromatographic procedure. Anal Biochem 1992;206:178-82.
29. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J-L, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 1993;90:7024-8.
30. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993;53:83-8.
31. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993;53:3860-4.
32. O'Malley BW, Jr., Chen S-H, Schwartz MR, Woo SLC. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995;55:1080-5.
33. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 1994;54:1503-6.
34. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993;53:4619-26.
35. Ge K, Xu L, Zheng Z, Xu D, Sun L, Liu X. Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Int J Cancer 1997;71:675-9.
36. Chang JW, Lee H, Kim E, Lee Y, Chung SS, Kim JH. Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. Neurosurgery 2000;47:931-8.
37. Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. Int J Urol 2001;8:S5-8.
38. Moriuchi S, Wolfe D, Tamura M, et al. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 2002; 9:584-91.
39. Boucher PD, Ostruszka LJ, Murphy PJM, Shewach DS. Hydroxyurea significantly enhances tumor growth delay in vivo with Herpes Simplex Virus thymidine kinase/Ganciclovir gene therapy. Gene Ther 2002;9:1023-30.
40. Yoshioka A, Tanaka S, Osamu H, et al. Deoxyribonucleoside triphosphate imbalance. J Biol Chem 1987; 262:8235-41.
41. 1/S transition state enzyme, in p53-mutated cells. Biochem Pharmacol 1998;55:1353-60.
42. Wildner OM, Blaese RM, Candotti F. Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus cellular thymidine kinase/ganciclovir system and thymidlate synthase inhibitors for the treatment of colon cancer. Cancer Res 1999;59:5233-8.
43. Klemperer HG, Haynes GR, Shedden WI, Watson DH. A virus-specific thymidine kinase on BHK-21 cells infected with herpes simplex virus. Virology 1967;31:120-8.
44. Bianchi V, Pontis E, Reichard P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 1986;261:16037-42.